Big Tobacco's Environmental Impact is 'Devastating', Says WHO

The WHO accused the tobacco industry of various means of environmental damage, from widespread deforestation to spewing out plastic and chemical waste Pascal POCHARD-CASABIANCA AFP/File
The WHO accused the tobacco industry of various means of environmental damage, from widespread deforestation to spewing out plastic and chemical waste Pascal POCHARD-CASABIANCA AFP/File
TT

Big Tobacco's Environmental Impact is 'Devastating', Says WHO

The WHO accused the tobacco industry of various means of environmental damage, from widespread deforestation to spewing out plastic and chemical waste Pascal POCHARD-CASABIANCA AFP/File
The WHO accused the tobacco industry of various means of environmental damage, from widespread deforestation to spewing out plastic and chemical waste Pascal POCHARD-CASABIANCA AFP/File

The tobacco industry is a far greater threat than many realize as it is one of the world's biggest polluters, from leaving mountains of waste to driving global warming, the WHO charged Tuesday.

The World Health Organization accused the industry of causing widespread deforestation, diverting badly needed land and water in poor countries away from food production, spewing out plastic and chemical waste as well as emitting millions of tons of carbon dioxide.

In its report released on World No Tobacco Day, the UN agency called for the tobacco industry to be held to account and foot the bill for the cleanup, reported AFP.

The report, "Tobacco: poisoning our planet", looks at the impacts of the whole cycle, from the growth of plants to the manufacturing of tobacco products, to consumption and waste.

While tobacco's health impacts have been well documented for decades -- with smoking still causing more than eight million deaths worldwide every year -- the report focuses on its broader environmental consequences.

The findings are "quite devastating," Ruediger Krech, WHO director of health promotion, told AFP, slamming the industry as "one of the biggest polluters that we know of."

The industry is responsible for the loss of some 600 million trees each year, while tobacco growing and production uses 200,000 hectares of land and 22 billion tons of water annually, the report found.

It also emits around 84 million tons of carbon dioxide, it said.

- 4.5 trillion cigarette butts -
In addition, "tobacco products are the most littered item on the planet, containing over 7,000 toxic chemicals, which leech into our environment when discarded," Krech said.

He pointed out that each one of the estimated 4.5 trillion cigarette butts that end up in our oceans, rivers, sidewalks and beaches every year can pollute 100 liters of water.

And up to a quarter of all tobacco farmers contract so-called green tobacco sickness, or poisoning from the nicotine they absorb through the skin.

Farmers who handle tobacco leaves all day consume the equivalent of 50 cigarettes worth of nicotine a day, Krech said.

This is especially worrying for the many children involved in tobacco farming.

"Just imagine a 12-year-old being exposed to 50 cigarettes a day," he said.

Most tobacco is grown in poorer countries, where water and farmland are often in short supply, and where such crops are often grown at the expense of vital food production, the report said.

Tobacco farming also accounts for about five percent of global deforestation, and drives depletion of precious water resources.

- Plastic pollution -
At the same time the processing and transportation of tobacco account for a significant share of global greenhouse gas emissions -- with the equivalent of one-fifth of the global airline industry's carbon footprint.

In addition, products like cigarettes, smokeless tobacco and e-cigarettes also contribute significantly to the global build-up of plastic pollution, WHO warned.

Cigarette filters contain microplastics -- the tiny fragments that have been detected in every ocean and even at the bottom of the world's deepest trench -- and make up the second-highest form of plastic pollution worldwide, the report said.

And yet, despite tobacco industry marketing, WHO stressed that there is no evidence filters provide any proven health benefits over smoking non-filtered cigarettes.

The UN agency urged policy makers worldwide to treat cigarette filters as single-use plastics, and to consider banning them.

It also decried that taxpayers around the world had been covering the towering costs of cleaning up the tobacco industry's mess.

Each year, China for instance dishes out around $2.6 billion and India around $766 million, while Brazil and Germany pay some $200 million each to clean up littered tobacco products, the report found.

WHO insisted that more countries should follow the so-called Polluter Pays Principle, as in France and Spain.

It is important, Krech said, that "the industry pay actually for the mess that they are creating."



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”